Comparative Pharmacology
Head-to-head clinical analysis: KEPPRA versus KEPPRA XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEPPRA versus KEPPRA XR.
KEPPRA vs KEPPRA XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levetiracetam binds to synaptic vesicle protein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability. It also inhibits high-voltage N-type calcium channels and reduces GABAergic and glycinergic inhibition.
Levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal excitability.
500 mg orally twice daily, titrated up to 1500 mg twice daily as tolerated.
1500 mg orally once daily (2 tablets of 750 mg). Extended-release formulation is taken once daily; immediate-release is dosed twice daily.
None Documented
None Documented
6-8 hours in adults; prolonged to 10-18 hours in renal impairment (CrCl <30 mL/min); clinical context: dosing interval adjustment required in renal disease.
7.1 ± 1.1 hours in adults; 10–11 hours in elderly; prolonged in renal impairment (up to 25 hours in severe renal failure).
Renal: 66% unchanged; 27% as inactive metabolite; 0.3% fecal.
Renal: 66% as unchanged drug; 27% as inactive metabolite (uch L057); biliary/fecal: negligible (<1%).
Category C
Category C
Antiepileptic
Antiepileptic